Clinical trialPhase 1Completed
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors
- Outcome
- Finished, no results posted
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- 18 June 2024
- Ended
- 8 July 2026
- Enrollment
- 27 participants
- Sites
- 9
- Primary outcomes
- Incidence of Treatment Emergent Adverse Events [Safety]; Incidence of dose limiting toxicities [Tolerability] (Phase 1); Determine Recommended Phase 2 Dose (RP2D) levels of APL-5125 in participants with selected advanced solid tumors (Phase 1)
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 5 October 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
Detailed description public domain (ClinicalTrials.gov)
The protocol was structured as a Phase 1/2 study with prespecified progression criteria informed by emerging data. Following completion of treatment for the last patient enrolled in Phase 1, it was determined that advancement to the Phase 2 portion of the protocol will not occur.